
    
      All patients will receive high-dose IL-2. Half the patients enrolled will be randomly
      selected to receive radiation therapy to up to three tumors prior to receiving high-dose
      IL-2. Among the first 20 patients enrolled, those assigned to receive radiation will receive
      a single dose of radiation and for patients 21-44, those assigned to receive radiation will
      receive 2 doses of radiation.
    
  